These two clearances mark an important step forward for Bioventus and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be ...

Among the 74 patients who completed peripheral nerve stimulation treatment, results showed 73% reported clinically meaningful reductions in back pain intensity at the end of the 2-month treatment.

Bioventus (Nasdaq:BVS) announced today that it received FDA 510(k) clearance for both its TalisMann and StimTrial offerings.

Peripheral nerve stimulation (PNS) has evolved with various applications and durations of therapy. In recent years, extensive data has been developed on a 60-day treatment using a novel approach.

Post this “This FDA clearance strengthens our mission to make peripheral nerve stimulation therapy appropriate for a broader patient population,” said Tom West, CEO and President of Nalu Medical.

There are no significant differences in pain relief, opioid reduction, and adverse events between TTP and DTP approaches to PNS implantation.

Data on chronic postoperative knee pain to be highlighted as a top abstract along with a first-ever look at SPRINT PNS in patients with migraine pain - ...

Scientists have revealed that the approach of electrical stimulation of the vagus nerve has minimal side effects. For instance, implanted vagus nerve stimulation devices are being used for decades ...

These include conventional therapies such as epidural steroid injections, joint and bursa injections, muscular trigger point injections, and peripheral nerve blocks. For patients with more severe or ...

“The stimulation technology is housed within the external pulse generator and is programmed by the physician at the time of implant to provide therapy for up to 60 days,” said Dr. Saulino.